VERAXA Biotech

At VERAXA Biotech (NASDAQ: VRXA) we are focused on pioneering antibody innovations to defeat cancer through next-generation antibody-based therapeutics.

[VERAXA Biotech @VERAXABiotech]

VERAXA strengthens patent portfolio with core BiTAC filings covering T cell engagers, ADCs, payloads & conjugation tech across the BiTAC-TCE and BiTAC-ADC platforms. Our dual-component architecture enhances tumor selectivity & safety. https://t.co/etsZiBk2ev
#Biotech $VRXA

[VERAXA Biotech @VERAXABiotech]

VXA-222 advances! Our bsADC program with @OmniAb has hit a key technical milestone, moving into its next phase. VXA-222 uses "AND-gate" logic to target 2 antigens on solid tumors with one molecule. Details: https://t.co/6NMan07NzJ

#VERAXA #Oncology #ADCs $VRXA

[VERAXA Biotech @VERAXABiotech]

We're thrilled to welcome Dr. Christoph Erkel as our new Chief Scientific Officer! His background and translational expertise will be key to advancing our #BiTAC® platform through clinical development.

For more see: https://t.co/eKY4czyoRz

$VRXA #Biotech #ADCs #TCEs

[VERAXA Biotech @VERAXABiotech]

🚀 $VRXA at the 4th ADC Linker & Conjugation Summit, Boston, July 28-30! On July 29, Dr. Paul Sauter will present on hydrophilic click chemistry for #ADC selectivity (9:30 a.m. ET) & join a panel on ADC toxicity strategy (12:00 p.m. ET).

Register: https://t.co/oXFtzi60uA

[VERAXA Biotech @VERAXABiotech]

$VRXA has received positive scientific advice from @PEI_Germany on our BiTAC-TCE technology, de-risking our path forward and building on encouraging #AACR2026 data showing a superior safety profile vs. traditional #TCEs.

Read more: https://t.co/yxfPhu2qTa

#VERAXA #Oncology

[VERAXA Biotech @VERAXABiotech]

$VRXA is teaming up with @Ardigen_SA to bring AI to our BiTAC® pipeline! Together, we’re optimizing cancer target pair selection for BiTAC-TCEs and future BiTAC-ADCs advancing precision #oncology designed to spare healthy tissue.

Read more: https://t.co/VB87Hzq1vU

[VERAXA Biotech @VERAXABiotech]

🧬 $VRXA looks ahead: doubling down on its BiTAC® platform, with VXA-102 targeted IND/CTA-ready by early 2028. Plans to monetize non-BiTAC assets to fuel growth, plus VXA-901 (AML) & HER2-ADC open for partnering.
Read more: https://t.co/B96f6iadjg
#Biotech #Oncology

[VERAXA Biotech @VERAXABiotech]

The right partner makes all the difference. #VERAXA has selected #ATUM, a leading US/West Coast CRO, to lead cell line development for our lead BiTAC®-TCE program, a first step toward manufacturing for preclinical & clinical material.

Read more: https://t.co/iGWJEtddGX
#Oncology

[VERAXA Biotech @VERAXABiotech]

#VERAXA Biotech is expanding its R&D hub in Heidelberg, Germany! A 60%+ increase in lab space will accelerate our BiTAC-TCE and BiTAC-ADC programs toward clinical development – right at the heart of world-class medical #oncology.

Read more: https://t.co/hozkBDBMQX

#Biotech

[VERAXA Biotech @VERAXABiotech]

We’re excited to share new proof‑of‑concept data for our BiTAC‑ADC technology.

Together with our BiTAC‑TCE platform, we have two differentiated technologies powering our approach to solid tumors therapies.

Read more: https://t.co/W8BMPN17Mh

#VERAXA #Biotech #Oncology

[VERAXA Biotech @VERAXABiotech]

🤝 Join #VERAXA Biotech at BIO International, San Diego, June 22-25!

Katharina Billian-Frey, Director of Business Development, is looking forward to discussing our BiTAC platform and how we’re changing cancer therapy with AND-gated strategies.

Schedule via BIO One-on-One!

[VERAXA Biotech @VERAXABiotech]

🎉 #VERAXA Biotech begins trading today on NASDAQ ($VRXA)!

As a public company, we’re pioneering cancer therapies via our BiTAC platform—dual-antigen, conditionally activated targeting designed to attack cancer cells while sparing healthy tissue.

https://t.co/SWsJzJ8PAz

[VERAXA Biotech @VERAXABiotech]

🚀 Major milestone for #VERAXA Biotech! We’ve secured $77.5M in financing to advance our next-gen cancer therapies and support our business combination with Voyager Acquisition Corp. Expected NASDAQ listing under $VRXA.

Read more: https://t.co/xwXB083wQv

[VERAXA Biotech @VERAXABiotech]

Excited to share #AACR26 data! Our #BiTAC platform delivers precision oncology with dual-targeting technology - AND-gate selectivity spares healthy cells while effectively targeting tumors. Strong results in both #TCE & #ADC approaches.

[VERAXA Biotech @VERAXABiotech]

At this year's @AACR Annual Meeting 2026, we will present preclinical data on two of our pipeline programs and share insights on the capabilities of our novel #BiTAC technology platform.

#VERAXA #VRXA #Oncology #ADCs #TCEs #AACR26